Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
platinum-based antineoplastic agent |
| gptkbp:administeredBy |
oral route
|
| gptkbp:ATCCode |
L01XA05
|
| gptkbp:CASNumber |
129580-63-8
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:cancer
|
| gptkbp:discoveredBy |
gptkb:Johnson_Matthey
|
| gptkbp:hasInChIKey |
QJQYQJXKQJYJQJ-UHFFFAOYSA-L
|
| gptkbp:hasMolecularFormula |
C6H14Cl2N2O4Pt
|
| gptkbp:hasSMILES |
CC(=O)O[Pt](Cl)(Cl)(NC1CCCCC1)(OC(C)=O)N
|
| gptkbp:hasUNII |
1A6F3F3F96
|
| https://www.w3.org/2000/01/rdf-schema#label |
satraplatin
|
| gptkbp:investigatedBy |
gptkb:cancer
prostate cancer |
| gptkbp:mechanismOfAction |
DNA crosslinking
|
| gptkbp:molecularWeight |
497.2 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL1201192
6918243 DB04841 |
| gptkbp:status |
not FDA approved
|
| gptkbp:synonym |
bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV)
JM-216 |
| gptkbp:bfsParent |
gptkb:Cisplatin
|
| gptkbp:bfsLayer |
7
|